DOCSLIB.ORG

Molecular Targets for Targeted Radionuclide Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Targets for Targeted Radionuclide Therapy Molecular targets for Targeted Radionuclide Therapy Stephen J Mather Barts and the London School of Medicine and Dentistry, Queen Mary University of London. [email protected] Changes in malignancy Levels may go up é or down ê What are we trying to achieve? • Selective Radiation dose delivery –é as high as possible to the tumour –ê as low as possible to normal tissues ê as low as possible to ‘important’ normal tissues How can we achieve this? • Choose the best target • Produce the best radiopharmaceutical • Use the best delivery strategy • Treat the best patients Features of the best targets • High expression in tumour – High density – High incidence – Good access • Low ‘expression’ in normal tissues Types of Targets • Extracellular • Transporters • Neurotransmitter receptors • Hormone receptors • Neuropeptide receptors • Growth Factor receptors • Tumour­associated Antibody epitopes • Intracellular • Metabolic pathways • DNA/RNA • Other organelles. Types of Targets • Extracellular • Transporters ­ Radioiodine • Neurotransmitter receptors • Hormone receptors • Neuropeptide receptors • Growth Factor receptors • TAA epitopes • Intracellular • Metabolic pathways • DNA/RNA • Other organelles Types of Targets • Extracellular • Transporters • Neurotransmitter receptors – peripheral e.g.mIBG • Hormone receptors • Neuropeptide receptors • Growth Factor receptors • TAA epitopes • Intracellular • Metabolic pathways • DNA/RNA • Other organelles Nor­adrenaline transporter LeuT Phaeochromocytoma vs neuroblastoma m­IBG Na + LAT1 Tumour expression Kyoichi Kaira Pathology, Research and Practice 2008, 204,553­561 Types of Targets • Extracellular • Transporters • Neurotransmitter receptors • Hormone receptors • Neuropeptide receptors ­ Somatostatin • Growth Factor receptors • TAA epitopes • Intracellular • Metabolic pathways • DNA/RNA • Other organelles G­protein coupled receptors Nature (2009) 459, 356­363 In vitro detection of somatostatin receptors in carcinoids. SSTR2 immunohistochemistry in ileal carcinoid A, Hematoxylin­eosin. B, Autoradiogram. C, nonspecific D, Hematoxylin­eosin. E, Autoradiogram showing sst 2 mRNA in the tumor by use of a 33P ­labeled probe. F, Control section Reubi, J. C. Endocr Rev 2003;24:389­427 Copyright ©2003 The Endocrine Society Somatostatin receptor expressing tumours • GH­producing pituitary Meningioma (sst ) adenoma (sst , sst ) 2 2 5 Neuroblastoma (sst ) • Nonfunctioning pituitary 2 Medulloblastoma (sst 2 ) adenoma (sst 3 > sst 2 ) Astrocytoma • Gut carcinoid (sst 2 > sst 1 , sst 5 ) Gastric carcinoma • Gastrinoma (sst 2 ) Hepatocellular carcinoma • Insulinoma Renal cell carcinoma Prostate carcinoma (sst ) • Paraganglioma (sst ) 1 2 Breast carcinoma • Pheochromocytoma (sst 2 ) Ovarian carcinoma • Medullary thyroid carcinoma Lymphoma • Small cell lung cancer (sst 2 ) Leiomyoma Endocrine Reviews (2003) 24 (4): 389­427 111 In­DOTATOC 68G a­DOTATOC 177 Lu­DOTA­TATE Kwekkeboom DJ et al Eur J Nucl Med Mol Imaging 2003 Mar;30(3):417­22. Tumour expression of neuropeptides Peptide Tumor type Somatostatin neuroendocrine tumors, non­Hodkgin lymphoma, melanoma, breast, a­MSH melanoma LHRH prostate, breast VIP/PACAP SCLC, colon, gastric, pancreatic CCK­2/Gastrin MTC, SCLC, pancreatic, astrocytoma, stromal ovarian cancer Opioid SCLC, neuroblastoma, breast Neurotensin SCLC, colon, exocrine pancreatic Bombesin/GRP SCLC, breast, colon, glioblastoma, prostate Substance P glioblastoma, astrocytoma, MTC, breast, intra­ and peritumoral blood vessels Reubi et al JNM 2005: 46: 67S Peptide autoradiography in breast cancer Reubi, J. C. Endocr Rev 2003;24:389­427 Copyright ©2003 The Endocrine Society CCKR2 radioscintigraphy Reubi, J. C. Endocr Rev 2003;24:389­427 Copyright ©2003 The Endocrine Society Types of Targets • Extracellular • Transporters • Neurotransmitter receptors • Hormone receptors • Neuropeptide receptors • Growth Factor receptors • TAA epitopes • Intracellular • Metabolic pathways • DNA/RNA • Other organelles Antibodies e.g. MUC1 µ MUC1 is a protein found on the surface of epithelial cells • Normal epithelial cells cover the protein with sugar residues • Tumour cells produce MUC1 lacking normal sugar coat µ MUC1 is the target for antibodies in the HMFG1 family • Only accessible in tumour cells, where protein core exposed Normal mucin Cancer mucin HMFG1­ Immunohistochemisty ­ Breast cancer HMFG1 vs SM3 R1549 phase II data in ovarian cancer • Significant survival benefit vs standard care (historical controls) Hird, V. et al. (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 68, 403­406. R1549 in ovarian cancer – phase III ‘SMART’ trial µ Phase III ‘SMART’ study examining survival benefit • R1549 (Pemtumomab) 30mCi i.p. + best std care vs best std care alone • Patients like those shown to benefit in phase II study µ Single pivotal study including ~ 420 patients µ Results published 2004 • No added benefit from RIT Phase II Trial of Pretargeted Yttrium­90­DOTA­Biotin 1. NR­LU­10 Antibody/Streptavidin 2. Biotin­galactose­HSA clearing agent 3. 110mCi/m2 Y­90­DOTA­Biotin Responses: 2 PR (8%); 4 SD (16%) Toxicity: Diarrhoea: 88% (up to grade IV) Nausea and Vomiting: 70% (mostly grade I­II) Fatigue and Anorexia: 70% (mostly grade I­II) Haematological: 100% (mostly grade I­II) HAMA, HASA. HACA: 100% Susan J. Knox, Clinical Cancer Research Vol. 6, 406–414, 2000 Some Molecular Targets for RIT in Haematology Antibody Radionuclide (Specificity Target Isotype antigen) cell/disease Anti­B1 I­131 CD­20 NHL Murine IgG2a (Tositumomab) antigen (Bexxar TM ) LYM­1 I­131 HLA­DR NHL Murine IgG2a antigen LL2 I­131 CD22 antigen NHL Murine IgG2a (Epratuzumab) Y­90 (transferrin R) Anti­CD33 I­131, CD­33 antigen Acute/chronic Humanized (Hu­M195) Bi­213 myelogenous murine Mab leukemia Ibritumomab Y­90 CD20 antigen NHL Murine IgGI Tiuxetan, (Zevalin TM IDEC­ Y2B8) . CD20 • Restricted to B­cell lineage • >90 % of B­cell malignancies • Highly expressed (100 ­200,000 copies per cell) • Not shed/modulated • No clonal selection • Direct induction of apoptosis Non­Hodgkin’s Lymphoma CT before and after Radioimmunotherapy 90 Y Zevalin Versus Rituximab Therapy: Response 100 90 80 ORR 70 80 80 PP==0.00.00022 60 CR 50 Patients 56 56 (%) 40 30 3030 20 PP==0.00.04 4 10 16 16 0 90Y Zevalin Rituximab Type I and II antibodies Antibody Type Apoptosis CDC ADCC adhesion Lipid rafts Rituximab I + +++ +++ + +++ B1 II +++ ­ ++ +++ ­ Contributions of radiation and cell signalling • Radiation: – External – 131­I anti MHC(II) • Signalling: – Anti­Id – Anti­CD19 Yong Du et al, Blood (2004) 103, 1485­1494 EBRT + anti­Id BCL1 A31 I­131 + anti­Id BCL1 A31 I­131 + CD19 HER receptor family EGF receptor Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron–Emitting Radiopharmaceutical 111In­DTPA–Human Epidermal Growth Factor. Journal of Nuclear Medicine (2007); 48: 1562­1570 Kristy E. Bailey, Danny L. Costantini, Zhongli Cai, Deborah A. Scollard, Zhuo Chen, Raymond M. Reilly and Katherine A. Vallis TABLE 1 Effect of Gefitinib on Binding, Internalization, and Nuclear Localization of 111I n­DTPA­hEGF in MDA­MB­468 Human Breast Cancer Cells Proportion (%) Proportion of cell­bound 111I n­ DTPA­hEGF (%) Treatment Radioactivity Cell­bound Radioactivity Radioactivity bound to cells radioactivity within within nucleus internalized by cytoplasm cells 111 In­DTPA­ 54.7 ± 8.6 76.9 ± 5.9 62.3 ± 9.5 14.6 ± 4.0 hEGF 111 In­DTPA­ 58.1 ± 2.8 81.1 ± 1.0 55.0 ± 6.2 26.0 ± 5.5 * hEGF + gefitinib * P < 0.05. Bailey et al: Journal of Nuclear Medicine (2007); 48: 1562­1570 Bailey et al: Journal of Nuclear Medicine (2007); 48: 1562­1570 Conclusions • A variety of targets have been successfully exploited for TRT • Many interesting targets remain • Expression on normal tissues may not be a limiting factor ­ non­receptor mediated mechanisms may dominate • Intrinsic radiosensitivity of tissues is important • Synergistic effects of radiation and cell­ signalling may be advantageous Thank you.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies Et Al
    US009 161992B2 (12) United States Patent (10) Patent No.: US 9,161,992 B2 Jefferies et al. (45) Date of Patent: Oct. 20, 2015 (54) P97 FRAGMENTS WITH TRANSFER 4,683.202 A 7, 1987 Mullis ACTIVITY 4,704,362 A 11/1987 Itakura et al. 4,766,075 A 8, 1988 Goeddeletal. (71) Applicant: biosis Technologies, Inc., Richmond 4,800,1594,784.950 A 11/19881/1989 MullisHagen et al. (CA) 4,801,542 A 1/1989 Murray et al. 4.866,042 A 9, 1989 Neuwelt (72) Inventors: Wilfred Jefferies, South Surrey (CA); 4,935,349 A 6/1990 McKnight et al. Mei Mei Tian, Coquitlam (CA): 4.946,778 A 8, 1990 Ladner et al. Timothy Vitalis, Vancouver (CA) 5,091,513 A 2f1992 Huston et al. 5,132,405 A 7, 1992 Huston et al. (73) Assignee: biOasis Technologies, Inc., British 5, 186,941 A 2f1993 Callahan et al. Columbia (CA) 5,672,683 A 9, 1997 Friden et al. 5,677,171 A 10, 1997 Hudziak et al. c - r 5,720,937 A 2f1998 Hudziak et al. (*) Notice: Subject to any disclaimer, the term of this 5,720,954. A 2f1998 Hudziak et al. patent is extended or adjusted under 35 5,725,856 A 3, 1998 Hudziak et al. U.S.C. 154(b) by 0 days. 5,770,195 A 6/1998 Hudziak et al. 5,772,997 A 6/1998 Hudziak et al. (21) Appl. No.: 14/226,506 5,844,093 A 12/1998 Kettleborough et al. 5,962,012 A 10, 1999 Lin et al.
    [Show full text]
  • Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
    CCR FOCUS Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends Martina Steiner and Dario Neri Abstract When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible. Monoclonal antibodies and their fragments, labeled with therapeutic radionuclides, have been used for many years in the development of anticancer strategies, with the aim of concentrating radioactivity at the tumor site and sparing normal tissues. This review surveys important milestones in the development and clinical implementation of radioimmunotherapy and critically examines new trends for the antibody-mediated targeted delivery of radionuclides to sites of cancer. Clin Cancer Res; 17(20); 6406–16. Ó2011 AACR. Introduction are immunogenic in humans and thus prevent repeated administration to patients [this limitation was subse- In 1975, the invention of hybridoma technology by quently overcome by the advent of chimeric, humanized, Kohler€ and Milstein (1) enabled for the first time the and fully human antibodies (7)]. Of more importance, production of rodent antibodies of single specificity most radioimmunotherapy approaches for the treatment (monoclonal antibodies). Antibodies recognize the cog- of solid tumors failed because the radiation dose deliv- nate
    [Show full text]
  • Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
    Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies Robert M. Sharkey, PhD; and David M. Goldenberg, ScD, MD Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey lular biology led the way with the development of mono- With the approval of 2 radiolabeled antibody products for the clonal antibodies and, more recently, with the engineering treatment of non-Hodgkin’s lymphoma (NHL), radioimmuno- of antibodies in various configurations with reduced immu- therapy (RIT) has finally come of age as a new therapeutic nogenicity. It is worth noting that antitumor antibodies modality, exemplifying the collaboration of multiple disciplines, remain one of the best means for selective binding to including immunology, radiochemistry, radiation medicine, suitable targets on cancer cells and have also stimulated the medical oncology, and nuclear medicine. Despite the many challenges that this new therapy discipline has encountered, study of other delivery forms, such as oligonucleotides or there is growing evidence that RIT can have a significant impact aptamers (6,7). However, the use of antibodies in radio- on the treatment of cancer. Although follicular NHL is currently immunotherapy (RIT) is still evolving, with the investiga- the only indication in which RIT has been proven to be effective, tion of new molecular constructs, new radionuclides and clinical trials are showing usefulness in other forms of NHL as radiochemistry, improved dosimetry, prediction of tumor well as in other hematologic neoplasms. However, the treatment response and host toxicities, and better targeting strategies of solid tumors remains a formidable challenge, because the to prevent or overcome host toxicities, particularly myelo- doses shown to be effective in hematologic tumors are insuffi- suppression.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Treatment of Cancer.Pptx
    5/3/15 Treatment of Cancer – Chemotherapy, Surgery, Radiation Cancer There is a crabgrass illustration – where you and Immunotherapy… find a batch of crabgrass in a beautiful yard… what do you do? • Cut it – Surgery • Burn it – Radiation • Poison it – Chemotherapy The best approach is to know what caused the crabgrass (it is a kind of grass) and treat it specifically – “Personalized Medicine or Molecular/Targeted Therapy” If we only had enough time Effective Therapies – may Aim of Therapy Cure, Control and/or Relieve the symptoms require better diagnosis • Neoadjuvant chemotherapy: Before • Most diagnosis depends on microscopic/ histopathological analysis (remember the surgery or radiation – to shrink tumor making staging?) it more effectively treated or removed • This method does NOT account for the • Adjuvant chemotherapy: treated after heterologous population of cells nor the surgery or radiation – To deal with undetected various mutations of driver/passenger genes, cells, microtumors… specific oncogenes or tumor suppressors. • Some markers are being used but not widely • Palliative chemotherapy: To treat patient and the number of oncologists that and reduce symptoms – improve quality of understand these markers and use them is life, not treat underlying cause or curative questionable except in most advanced cases “Targeted” Cancer Treatment Cancer Targets How does it work? Attack targets which are specific for the cancer cell and are critical for its survival or for its malignant behavior Why is it better than chemotherapy? More specific for cancer cells – chemotherapy hits rapidly growing cells not all cancer cells grow that rapidly some normal cells grow rapidly Possibly more effective From National Cancer Institute, US National Institutes of Health.
    [Show full text]
  • Translational Research in Surgical Disease
    REVIEW ARTICLE Translational Research in Surgical Disease Alexander Stojadinovic, MD; Nita Ahuja, MD; Susanna M. Nazarian, MD, PhD; Dorry L. Segev, MD; Lisa Jacobs, MD; Yongchun Wang, MD; John Eberhardt, MD; Martha A. Zeiger, MD Objective: To review cutting-edge, novel, imple- geon familiar with cutting-edge and novel research in their mented and potential translational research and to pro- field of expertise and interest. vide a glimpse into rich, innovative, and brilliant ap- proaches to everyday surgical problems. Data Synthesis: Articles that met criteria were sum- marized in the manuscript. Data Sources: Scientific literature and unpublished re- sults. Conclusions: Multiple avenues have been used for the dis- coveryofimprovedmeansofdiagnosis,treatment,andoverall Study Selection: Articles reviewed were chosen managementofpatientswithsurgicaldiseases.Theseavenues based on innovation and application to surgical dis- have incorporated the use of genomics, electrical impedence, eases. statistical and mathematical modeling, and immunology. Data Extraction: Each section was written by a sur- Arch Surg. 2010;145(2):187-196 HE FOLLOWING REVIEW OF risk of malignancy ranges from 5% to 10% cutting-edge, novel, imple- for follicular lesions (atypia) of undeter- mented and potential trans- mined significance, 20% to 30% for fol- lational research is meant to licular neoplasms, and 50% to 75% for provide a glimpse into rich, nodules with cytological features suspi- Tinnovative, and brilliant approaches to ev- cious of malignancy.1 Because cytology re- eryday surgical problems. It is written pri- sults are indeterminate in up to one- marily by young, innovative surgical sci- third of FNABs, the frequency of diagnostic entists in their field of interest and often or nontherapeutic thyroid resection is sig- in their field of research.
    [Show full text]
  • IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
    Pure Appl. Chem., Vol. 84, No. 5, pp. 1113–1295, 2012. http://dx.doi.org/10.1351/PAC-REC-11-06-03 © 2012 IUPAC, Publication date (Web): 16 February 2012 IUPAC glossary of terms used in immunotoxicology (IUPAC Recommendations 2012)* Douglas M. Templeton1,‡, Michael Schwenk2, Reinhild Klein3, and John H. Duffus4 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; 2In den Kreuzäckern 16, Tübingen, Germany; 3Immunopathological Laboratory, Department of Internal Medicine II, Otfried-Müller-Strasse, Tübingen, Germany; 4The Edinburgh Centre for Toxicology, Edinburgh, Scotland, UK Abstract: The primary objective of this “Glossary of Terms Used in Immunotoxicology” is to give clear definitions for those who contribute to studies relevant to immunotoxicology but are not themselves immunologists. This applies especially to chemists who need to under- stand the literature of immunology without recourse to a multiplicity of other glossaries or dictionaries. The glossary includes terms related to basic and clinical immunology insofar as they are necessary for a self-contained document, and particularly terms related to diagnos- ing, measuring, and understanding effects of substances on the immune system. The glossary consists of about 1200 terms as primary alphabetical entries, and Annexes of common abbre- viations, examples of chemicals with known effects on the immune system, autoantibodies in autoimmune disease, and therapeutic agents used in autoimmune disease and cancer. The authors hope that among the groups who will find this glossary helpful, in addition to chemists, are toxicologists, pharmacologists, medical practitioners, risk assessors, and regu- latory authorities. In particular, it should facilitate the worldwide use of chemistry in relation to occupational and environmental risk assessment.
    [Show full text]
  • Targeted Radionuclide Therapy of Human Tumors
    Review Targeted Radionuclide Therapy of Human Tumors Sergey V. Gudkov 1,2,3,*, Natalya Yu. Shilyagina 1, Vladimir A. Vodeneev 1 and Andrei V. Zvyagin 1,4 Received: 26 September 2015; Accepted: 22 December 2015; Published: 28 December 2015 Academic Editors: William Chi-shing Cho and Anthony Lemarié 1 Laboratory of Optical Theranostics, Lobachevsky Nizhny Novgorod State University, Gagarin Ave. 23, Nizhny Novgorod 603950, Russia; [email protected] (N.Y.S.); [email protected] (V.A.V.); [email protected] (A.V.Z.) 2 Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Institutskaya St, 3, Pushchino, Moscow 142290, Russia 3 Prokhorov Institute of General Physics, Russian Academy of Sciences, Vavilova St, 38, Moscow 119991, Russia 4 ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, Sydney 2109, Australia * Correspondance: [email protected]; Tel.: +7-4967-739-497 Abstract: Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.
    [Show full text]
  • Improving the Efficacy of Antibody-Based Cancer Therapies
    REVIEWS IMPROVING THE EFFICACY OF ANTIBODY-BASED CANCER THERAPIES Paul Carter A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies. PHAGE DISPLAY Antibodies are finally realizing their potential as anti- relapsed low-grade non-Hodgkin’s lymphoma,only Technology for displaying a cancer therapeutics: since 1995, five antibodies have about half of the patients responded7. This included protein (or peptide) on the been approved for the treatment of cancer (TABLE 1). 6% COMPLETE and 42% PARTIAL RESPONSES from 166 surface of a bacteriophage, Additional approvals will surely follow from among patients, similar results to those obtained with a single- which contains the gene(s) 1,2 that encodes the displayed the 20 or so antibodies now in oncology trials , agent cytotoxic chemotherapeutic in this group of protein(s), thereby physically including 10 that have advanced to Phase III trials or patients. These data, combined with the mild toxicity linking the genotype and further (TABLE 1). profile of Rituxan, led the United States Food and Drug phenotype. The emergence of antibodies as therapeutics was Administration (FDA) to approve Rituxan for relapsed VALENCY made possible by the advent of technologies designed to indolent lymphoma. Unfortunately, the median 7 For antibody-derived overcome the main limitations of mouse monoclonal RESPONSE DURATION was only about 12 months . In a Phase molecules, this refers to the antibodies (mAb) — immunogenicity of these foreign III study of trastuzumab (Herceptin) — a humanized number of binding sites for the proteins in patients, inefficient effector functions (see mAb against the receptor tyrosine kinase ERBB2 (also cognate antigen(s).
    [Show full text]
  • Ovarian Cancer
    Systemic Therapy of Epithelial Ovarian Cancer Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 5th ESO-ESMO Eastern European and Balkan Region Masterclass in Medical Oncology, Belgrade, June 15-20, 2018 Conflict of Interest Disclosure • Participates in Advisory Boards of: AstraZeneca, Incyte, Innate Pharma, Merck KGaA, Merck Sharp & Dome Corp, PCI Biotech, Synthon Biopharmaceuticals, • Lecturer fee from: Merck-Serono, Sanofi, Bristol Myers Squibb Epithelial Ovarian Cancer Milestones • Surgery according to FIGO guidelines – At least LND and peritoneal staging in early ovarian cancer – Upfront maximal surgical debulking in advanced ovarian cancer • Chemotherapy evolution – Introduction of platinum compounds – Introduction of taxanes • The set-up of international collaboration (1997) Ovarian Cancer: FIGO Staging Surgical exploration Diagnostic • Vertical incision • Peritoneal fluid → cytology (or saline irrigation) • Scrupulous inspection - right diaphragm - liver, serosa, parenchyma • Biopsies of contralateral ovary, retroperitoneal LN and suspicious changes on the peritoneum, omentum Therapeutic • Early disease – TAH + BSO, omentectomy, LND • Advanced disease – debulking surgery FIGO Staging (2017) of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma IA Confined to one ovary, intact capsule, no tumor on surface (Ov;FT), no malignant cells in ascites or peritoneal washings IB Confirmed to both ovaries (same criteria as IA) IC IA or IB + surgical spill/capsule rupture/tumor on surface/pos.
    [Show full text]
  • A61K9/51 (2006.01) — with International Search Report (Art
    ) ( 2 (51) International Patent Classification: Published: A61K9/51 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US20 19/033 875 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (22) International Filing Date: 24 May 2019 (24.05.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/676,169 24 May 2018 (24.05.2018) US (71) Applicant: ELEKTROFI, INC. [US/US]; 75 Kneeland Street, 14th Floor, Boston, MA 021 11 (US). (72) Inventors: COFFMAN, Chase; 86 Worcester Street, Unit 3, Boston, MA 021 18 (US). CHARLES, Lyndon; 600 Main St Apt 3, Medford, MA 02155 (US). BROWN, Paul; 156 W 6th St, Unit 2, Boston, MA 02127 (US). DADON, Daniel, Benjamin; 2 Garden Court, Apt. 1, Cambridge, MA 02138 (US). LIU, Lisa; 111 Bartlett Street, Apt 2, Somerville, MA 02145 (US). SHADBAR, Sadiqua; 1307 Commonwealth Avenue, Apt 9, Allston, MA 02135 (US). SUDRIK, Chaitanya; 7 1 Elm Street, Apartment #2, Cam¬ bridge, MA 02139 (US). (74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 021 10 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. A61K 31/437 (2018.01) 11 A61K 31/496 (2018.01) N° 18380 A61K 31/5377 (2018.01) A61P 35/02 (2018.01) FASCICULE DE BREVET D'INVENTION 21 Numéro de dépôt : 1201700302 73 Titulaire(s): PCT/US2016/015727 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 29/01/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): US n° 62/111,604 du 03/02/2015 72 DI PAOLO Julie A. (US) TUMAS Daniel B. (US) JONES Randall Mark (US) 24 Délivré le : 31/08/2018 74 Mandataire: GAD CONSULTANTS SCP, P.O. Box 13448, YAOUNDE (CM). 45 Publié le : 02.11.2018 54 Titre: Combination therapies for treating cancers. 57 Abrég é : Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration entospletinib and a Bcl-2 inhibitor, such as venetoclax, navitoclax, and ABT-737. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18380 COMBINATION THERAPIES FOR TREATING CANCERS FIELD The present disclosure relates generally to therapeutics and compositions for treating cancers, and more specifically to the use of Spleen Tyrosine Kinase (Syk) inhibitors 5 in combination with B-cell CLL/lymphoma 2 (Bc1-2) inhibitors for treating cancers. BACKGROUND Syk inhibitors useful as anticancer agents include entospletinib, discussed in Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL), Sharman et al., Blood, 124(21), Dec.
    [Show full text]